Although there are no canonical Myc-binding sites (E boxes, CACGTG) in the region 1.2 kb upstream of the FasL gene [12] , examination of the FasL promoter sequence revealed a site that has been described as a putative binding site for c-Myc in a number of genes, including EF-II, Hsp70 and c-Myc itself (Figure 1a ). To examine whether this element was responsive to c-Myc and could drive expression of the FasL promoter, we coexpressed the 1.2 kb FasL promoter reporter construct [12] with a c-Myc expression vector in Jurkat T cells. We observed a significant activation of the FasL promoter in response to elevated expression of c-Myc (Figure 1b) . To verify the specificity of this observation, we generated a mutant FasL promoter construct containing base changes within the putative Myc-binding region (ATTATCAC-TAG, the substituted bases are italicized). This mutation effectively eliminated the response of the FasL promoter to c-Myc co-expression ( Figure 1c ) and to T-cell activation signals mimicked by phorbol 12-myristate 13-acetate (PMA) plus ionomycin (data not shown). 
Results and discussion
Although there are no canonical Myc-binding sites (E boxes, CACGTG) in the region 1.2 kb upstream of the FasL gene [12] , examination of the FasL promoter sequence revealed a site that has been described as a putative binding site for c-Myc in a number of genes, including EF-II, Hsp70 and c-Myc itself ( Figure 1a ). To examine whether this element was responsive to c-Myc and could drive expression of the FasL promoter, we coexpressed the 1.2 kb FasL promoter reporter construct [12] with a c-Myc expression vector in Jurkat T cells. We observed a significant activation of the FasL promoter in response to elevated expression of c-Myc (Figure 1b) . To verify the specificity of this observation, we generated a mutant FasL promoter construct containing base changes within the putative Myc-binding region (ATTATCAC-TAG, the substituted bases are italicized). This mutation effectively eliminated the response of the FasL promoter to c-Myc co-expression ( Figure 1c ) and to T-cell activation signals mimicked by phorbol 12-myristate 13-acetate (PMA) plus ionomycin (data not shown). Previous observations had indicated a potential role for Max in the activity of c-Myc in regulating FasL transcription and induction of AICD [9, 10] . To examine more directly the possibility that the site we have identified in the FasL promoter binds to c-Myc and that its binding partner, Max, may also be required, we used glutathione-Stransferase (GST) fusions of Myc and Max proteins in the EMSA. Myc and Max proteins bound as heterodimers to both the non-canonical and the consensus site in the FasL promoter ( Figure 2c ). However, c-Myc alone was only able to recognise and bind the consensus sequence. Max alone was unable to bind either the non-canonical or the consensus Myc sites. These data indicate that the non-canonical c-Myc-binding motif selectively binds Myc-Max heterodimers. Confirmation that recombinant GST-Myc and Max (no GST tag) heterodimers formed a complex with oligonucleotides containing canonical or non-canonical Myc sites was shown by the detection of a supershifted complex using an anti-GST antibody ( Figure 2d ).
We reasoned that if the sequence in the FasL promoter is a bona fide Myc-responsive element, then it might substitute for Myc-responsive elements in other promoters. The ODC promoter responds to c-Myc and contains two canonical Myc-binding sites [11] . We generated constructs in which the Myc-binding sites in the ODC promoter (denoted #1 and #2) were mutated and/or replaced with the non-canonical c-Myc sequence from the FasL promoter ( Figure 3a) . As shown in Figure 3b , the wild-type ODC promoter (ODCwt) was induced by co-expression with c-Myc, and mutation of both of the Myc-binding sites (ODC∆5A) decreased this responsiveness [11] . When one (ODC∆5A-FasL#1) or both (ODC∆5A-FasL#1,#2) the mutated sites were replaced with the non-canonical Myc sequence, the Myc responsiveness of the ODC promoter was restored to a level greater than that seen with the wild-type promoter. We conclude that the noncanonical Myc-binding site from the FasL promoter can functionally replace canonical Myc-binding sites in an established Myc-responsive promoter.
We also performed the experiment by sequential exchange of the two wild-type sequences in the ODC promoter with the non-canonical binding sequence from the FasL-promoter (ODCwt-FasL#1, ODCwt-FasL#2 and ODCwt-FasL#1,#2). This generated a series of reporter constructs that all exhibited an enhanced responsiveness to c-Myc (Figure 3c ) compared with ODCwt. These data further implicate this region of the FasL promoter as a Myc-responsive element.
We have previously shown that c-Myc is required for AICD and FasL expression in T cells and T-cell hybridomas [8] [9] [10] . Together with the data presented here, our results implicate a non-canonical site in the FasL promoter in binding the Myc-Max heterodimer, and which is necessary but not sufficient for expression of the FasL gene.
Other transcription factors that are activated upon T-cell receptor (TCR) ligation and that participate in FasL gene expression include NF-AT, EGR-2 and NF-kB [13] . This activation-induced FasL mRNA expression proceeds in the presence of cycloheximide [14] , which suggests that the essential factors (including c-Myc) act directly to drive the FasL promoter rather than through activation and induced expression of other transcription factors. Together, these transcription factors co-operate to optimally induce activation of the FasL promoter, leading to gene expression. When FasL is expressed, it ligates its cell-surface receptor Fas, which in turn engages the appropriate intracellular machinery, culminating in activation of caspases and apoptotic death of the cell [5] [6] [7] .
Brief Communication 1207 The site we have identified as a Myc-responsive site in the FasL promoter is similar or identical to other sites that have previously been suggested to be Myc responsive (see Figure 1a ). This site, however, is only remotely similar to the well-established E box present in a number of Mycresponsive promoters (including the ODC promoter) [11] that were identified by direct binding of Myc to randomized oligonucleotides [15] . Why was the site that we have identified not detected as Myc binding in such studies? One possible answer is suggested by the observation shown in Figure 2c in which oligonucleotides containing this sequence failed to bind recombinant c-Myc (or did so very poorly), but instead bound recombinant Myc-Max heterodimer effectively. Notably, one of our earlier studies described the requirement for Myc-Max heterodimers in AICD [10] . This difference in binding by Myc versus Myc-Max (Figure 2c ) may help account for the difference in detection of sites such as we have identified versus the more conventional E-box-related sites.
We recently reported that transforming growth factor-β (TGF-β) suppresses the transcriptional activation of FasL and AICD by the direct inhibition of c-Myc expression [16] . Furthermore, interleukin-2 (IL-2) sensitizes T cells to AICD and promotes elevated c-Myc expression [17] , making it tempting to speculate that c-Myc may contribute to this sensitization process. These observations support our belief that c-Myc plays a key role in regulating FasL expression under physiologically relevant situations.
Why should FasL expression in lymphocytes be linked to the expression and function of c-Myc? Only activated, proliferating cells, and not resting lymphocytes, express c-Myc. As clonal expansion forms the basis of immune responses, it is only the proliferating cells that may represent a threat to the body should they happen to be autoreactive (or even hyper-reactive, as these will also cause extensive bystander damage). Re-stimulation of activated cells therefore induces FasL, which in turn serves to check cellular expansion by induction of apoptosis. Alternatively (and non-exclusively), activated, proliferating lymphocytes that take on effector functions do so, in part, through the expression of FasL (except in this case they are resistant to Fas-mediated death), which functions to kill Fas-expressing cells with which they come in contact. By limiting this expression to proliferating cells, it serves as a fail-safe mechanism to ensure that once the cells cease to express c-Myc (for example, at the cessation of the response) expression of this lethal molecule will also cease.
